ScreenerHero

ISOFOL Isofol Medical AB (publ)

STO · SE · Healthcare · Biotechnology · isofolmedical.com
0.7890SEK+4.50%Mkt Cap: 24.19M $P/E: —

Isofol Medical AB (publ) operates as a clinical stage biotech company. It develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. The company was incorporated in …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$127.24BUSDP/E 29.3
REGN
Regeneron Pharmaceuticals, Inc.
$76.05BUSDP/E 18.3
MRNA
Moderna, Inc.
$74.84BUSD
ARGX
argenx SE
$56.77BUSDP/E 37.1
ARGX
argenx SE
$58.21BUSDP/E 35.5
UCB
UCB SA
$41.93BUSDP/E 17.9
RVMD
Revolution Medicines, Inc.
$42.84BUSD
ONC
BeOne Medicines AG
$41.27BUSDP/E 64.9
RPRX
Royalty Pharma plc
$32.61BUSDP/E 30.0
ALNY
Alnylam Pharmaceuticals, Inc.
$29.97BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.66BUSD
BNTX
BioNTech SE
$24.05BUSD
GMAB
Genmab A/S
$23.24BUSDP/E 29.8
INSM
Insmed Incorporated
$22.98BUSD
GMAB
Genmab A/S
$22.23BUSDP/E 30.6
INCY
Incyte Corporation
$22.85BUSDP/E 14.4
JAZZ
Jazz Pharmaceuticals plc
$15.02BUSDP/E 15.9
ASND
Ascendis Pharma A/S
$14.87BUSDP/E 17.3
EXEL
Exelixis, Inc.
$14.45BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$13.81BUSD

Key Statistics

Company
Market Cap24.19M USD
Enterprise Value11.89M USD
Revenue (TTM)—
Gross Profit-3.84M USD
Net Income (TTM)-5.18M USD
Revenue/Share—
Last Price0.7890 SEK
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees7
CountrySE
SectorHealthcare
IndustryBiotechnology
ISINSE0009581051
Valuation
P/E (Trailing)—
P/E (Forward)-14.92
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B2.52
EPS (TTM)-0.20
EPS (Forward)-0.05
52W Range
0.551554% of range0.9900
52W High0.9900 SEK
52W Low0.5515 SEK
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-50.22%
ROA-41.86%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-4.97M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-12.99%
Net Debt-10.98M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio5.17
Quick Ratio5.11
Book Value/Sh0.30 SEK
Cash/Share0.36 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 SEK
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating0.0 (Hold)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)1.700 SEK
Upside (mean)+115.5%
Target Range1.700 SEK – 1.700 SEK
# Analysts1
Ownership
Shares Out.320.49M
Float228.15M
Insiders26.07%
Institutions15.00%
Technical
SMA 500.7920 (-0.4%)
SMA 2000.7213 (+9.4%)
Beta1.02
S&P 52W Chg14.58%
Avg Vol (30d)339.12K
Avg Vol (10d)210.74K
Technical Indicators
RSI (14)54.8
MACD-0.0015
MACD Signal-0.0029
MACD Hist.+0.0013
BB Upper0.8172 SEK
BB Middle0.7620 SEK
BB Lower0.7068 SEK
BB Width14.48%
ATR (14)0.0407 SEK
Vol Ratio (20d)1.01x